CClinicalTrials.gg
Sign In
Status unknownNCT05590533Updated Oct 21, 2022

Turkish Version of F-2-MS

An observational study in Cultural Adaptation, Reliability and Validity, sponsored by Pamukkale University. Status unknown. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-10-21.

Sponsored by Pamukkale University · Observational

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
180
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The aims of this study were to perform cultural adaptation of the F-2-MS and provide information regarding the factor structure, reliability and validity of the instrument in Turkish speaking patients with Multiple Sclerosis.

02

Conditions studied

  • Cultural Adaptation
  • Reliability
  • Validity
  • Multiple Sclerosis
  • Fatigue

Browse trials for

03

In context

Multiple Sclerosis

3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.

This study's planned enrollment of 180 is above the median of 100 across 1,016 observational studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Pamukkale University is the lead sponsor of 331 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with multiple sclerosis with an EDSS score of 5 or less

Inclusion criteria

  • Individuals aged between 20-65 years, with an EDSS score of 0-5, who have not had an attack in the last 2 months, who have no cognitive problems (a score of 6 or more according to the Hodkinson Mental Test), who do not have additional neurological diseases other than MS, and who volunteer to participate in the study will be included.

Exclusion criteria

Exclusion Criteria:

  • Individuals with an EDSS score greater than 5, who are in the attack period, who have vestibulosupressant or drug or alcohol use habits that cause neuropathy, and who have communication problems will be excluded from the study.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No

Interventions

  • OtherCultural adaptation, reliability and validity

    Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the F-2-MS

06

What researchers measure

Primary outcomes

  1. F-2-MS Scale

    F-2-MS is a novel scale to assess fatigue and perceived fatigability in patients with MS

    Time frame: 10 minutes

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05590533
Lead sponsor
Pamukkale University
Responsible party
Ayşe Ünal (Assoc. Prof., Pamukkale University) — Principal investigator
First posted
Oct 21, 2022
Start date
Nov 2022 (estimated)
Primary completion
Apr 2023 (estimated)
Completion
May 2023 (estimated)
Last update
Oct 21, 2022

Study contacts

Ayşe Ünal, Assoc. Prof.
Contact
pt.aunal@gmail.com
+90(258)2964297

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Multiple Sclerosis→

Other studies from this sponsor

Pamukkale University

Start the discussion